Neumora Therapeutics (NASDAQ:NMRA) Announces Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Neumora Therapeutics (NASDAQ:NMRA) posted its quarterly earnings data on Thursday. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.09, Zacks reports.

Neumora Therapeutics Price Performance

Shares of NASDAQ NMRA opened at $1.49 on Friday. The company has a 50 day simple moving average of $2.44 and a 200 day simple moving average of $8.64. The firm has a market cap of $240.73 million, a PE ratio of -0.80 and a beta of 2.59. Neumora Therapeutics has a 1 year low of $1.30 and a 1 year high of $21.00.

Analyst Ratings Changes

NMRA has been the subject of several recent analyst reports. HC Wainwright cut their price objective on shares of Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday. William Blair reaffirmed an “outperform” rating on shares of Neumora Therapeutics in a research report on Wednesday, January 15th. Needham & Company LLC reissued a “buy” rating and issued a $5.00 target price on shares of Neumora Therapeutics in a report on Tuesday. Royal Bank of Canada reissued a “sector perform” rating and issued a $4.00 target price on shares of Neumora Therapeutics in a report on Tuesday. Finally, Stifel Nicolaus cut shares of Neumora Therapeutics from a “buy” rating to a “hold” rating and dropped their target price for the stock from $6.00 to $2.00 in a report on Friday. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Neumora Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $10.14.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.